Onglyza is a drug that helps control blood sugar levels. It’s primarily used by people with type 2 diabetes and is taken orally. It works to regulate insulin levels produced by the body after eating. The drug was first introduced on the market in 2007 and was known as Saxaglipton.
In 2016, the FDA issued a warning about the drug’s association with heart failure risk. People with a history of heart disease or kidney disease have an increased risk of heart failure symptoms on the drug.
Patients taking Onglyza should contact their doctor if they develop:
- Unusual shortness of breath during daily activities
- Trouble breathing when lying down
- Tiredness, weakness, or fatigue
- Weight gain with swelling in the ankles, feet, legs, or stomach
Other adverse affects associated with Onglyza:
- Upper respiratory tract infection
- Urinary tract infection
If you are taking Onglyza or considering using it in the future, the FDA recommends discussing these additional risks with your doctor.